Literatur
- 1
Thun M J, Namboodiri M M, Heath C W.
Aspirin use and reduced risk of fatal colon cancer.
N Engl J Med.
1991;
325
1593-1596
- 2
Khuder S A, Mutgi A B.
Breast cancer and NSAID use: a meta-analysis.
Br J Cancer.
2001;
84
1188-1192
- 3
Hial V, Horakova Z, Shaff F E, Beaven M A.
Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable
tumors in mouse.
Eur J Pharmacol.
1976;
37
367-376
- 4
Kudo T, Narisawa T, Abo S.
Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors
in rats.
Gann.
1980;
71
260-264
- 5
Boolbol S K, Dannenberg A J, Chadburn A, Martucci C, Guo X J, Ramonetti J T, Abreu-Goris M,
Newmark H L, Lipkin M L, DeCosse J J, Bertagnolli M M.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine
model of familial adenomatous polyposis.
Cancer Res.
1996;
56
2556-2560
- 6
Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan E S, Takei Y, Nagano K, Hori M.
Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction
of apoptosis in nude mice.
Am J Physiol.
1998;
274
G1061-G1067
- 7
Sheng H, Shao J, Kirkland S C, Isakson P, Coffey R J, Morrow J, Beauchamp R D, DuBois R N.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
J Clin Invest.
1997;
99
2254-2259
- 8
Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B,
Hauptmann S.
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian
carcinoma.
Am J Pathol.
2002;
160
893-903
- 9
Denkert C, Fürstenberg A, Daniel P T, Koch I, Köbel M, Weichert W, Siegert A, Hauptmann S.
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory
drug NS-398, but not by COX-2 specific RNA interference.
Oncogene.
2003;
22
8653-8661
- 10
Seo S S, Song Y S, Kang D H, Park I A, Bang Y J, Kang S B, Lee H P.
Expression of cyclooxygenase-2 in association with clinicopathological prognostic
factors and molecular markers in epithelial ovarian cancer.
Gynecol Oncol.
2004;
92
927-935
- 11
Raspollini M R, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A, Taddei G L.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer:
correlation with clinical outcome.
Gynecol Oncol.
2004;
92
806-812
- 12
Erkinheimo T L, Lassus H, Finne P, van Rees B P, Leminen A, Ylikorkala O, Haglund C,
Butzow R, Ristimaki A.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53
and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Clin Cancer Res.
2004;
10
538-545
Carsten Denkert
Institut für Pathologie, Universitätsklinikum Charité, Berlin
Schumannstr. 20/21
10117 Berlin
Phone: 0 30/4 50-5 36-0 47
Fax: 0 30/4 50-5 36-9 00
Email: carsten.denkert@charite.de
